NEWARK, N.J., July 21 /PRNewswire-FirstCall/ -- BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), a specialty chemical technology based Life Science Company announced today that at ATS Labs using the required EPA protocol testing, BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial passed the difficult Quantitative Disk Carrier test by totally eradicating all 5.4 million spores of Clostridium difficile (C.diff) present in this test in 10 minutes at room temperature. Few antimicrobials are capable of passing this test. These Validated Results Now Give Ygiene(TM) Antimicrobial Unique Performance Status Among All Disinfectants.
Clostridium difficile (C.diff) is the most difficult to eliminate spore form of health threatening microorganisms present in most health care facilities globally. Many leading commercially available antimicrobials currently used in the global health care arena are ineffective at eliminating Clostridium difficile spores. This is one reason why hospital acquired infections (HAI) are such a serious and growing problem. In the USA alone about 2 million patients annually are afflicted with hospital acquired infections (HAI) resulting in approximately 100,000 deaths. Worldwide hospital acquired infections are on the rise and will lead to hundreds of thousands of needless deaths annually. BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial will be a significant part of the future solution for controlling hospital acquired infections in general and the expedient total restoration of areas found to be contaminated with Clostridium difficile (C.diff). Currently health care facilities globally have severely limited options for eliminating this dangerous spore.
Chief Scientist for BioNeutral Group, Inc., Dr. Andy Kielbania stated, "These independent ATS Labs test results completely validate our internal product development efforts. The level of efficacy demonstrated by these independent tests is exceptional. Passing this difficult EPA required protocol test for the elimination of Clostridium difficile spores is consistent with the ability of our Ygiene(TM) Hospital Grade Antimicrobial to address a very serious, however unmet need in the global health care arena. We believe our Ygiene(TM) Hospital Grade Antimicrobial will significantly contribute to the saving of many lives."
BioNeutral Group CEO Stephen J. Browand commented, "There is little I can add that will enhance anyone's understanding of a perfect independent test score, against the very dangerous and resilient C.diff microorganism. These ATS lab results stand firmly on their own accord and what is now public record. I will only add that the creation of our Ygiene(TM) formula by Dr. Kielbania and his entire scientific team make me very proud to be a part of the BioNeutral Group."
About ATS Labs:
ATS Labs, http://www.ats-labs.com is a leading internationally recognized lab used by the developers and users of antimicrobial products. They provide comprehensive antimicrobial service and their superior client service and scientific data have earned them a distinguished record of acceptance with regulatory agencies in the U.S., Canada and the world.
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.
More information about the Company may be found at www.bioneutralgroup.com.
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.
Contact Information BioNeutral Group, Inc. Stephen J. Browand, President and CEO firstname.lastname@example.org Investor Relations Aimee Boutcher 973 239-2878 email@example.com
|SOURCE BioNeutral Group, Inc.|
Copyright©2009 PR Newswire.
All rights reserved